CN110141557A - 氢化可的松控制释放制剂 - Google Patents

氢化可的松控制释放制剂 Download PDF

Info

Publication number
CN110141557A
CN110141557A CN201910452557.1A CN201910452557A CN110141557A CN 110141557 A CN110141557 A CN 110141557A CN 201910452557 A CN201910452557 A CN 201910452557A CN 110141557 A CN110141557 A CN 110141557A
Authority
CN
China
Prior art keywords
hydrocortisone
purposes
composition
pharmaceutical composition
adrenal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910452557.1A
Other languages
English (en)
Chinese (zh)
Inventor
希珀·华单
理查德·罗斯
马丁·惠特克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immedica UK Ltd
Original Assignee
Diurnal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diurnal Ltd filed Critical Diurnal Ltd
Publication of CN110141557A publication Critical patent/CN110141557A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201910452557.1A 2012-02-13 2013-02-12 氢化可的松控制释放制剂 Pending CN110141557A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1202433.7A GB201202433D0 (en) 2012-02-13 2012-02-13 Controlled drug release
GB1202433.7 2012-02-13
US201261599704P 2012-02-16 2012-02-16
US61/599,704 2012-02-16
US201261600958P 2012-02-20 2012-02-20
US61/600,958 2012-02-20
CN201380008921.6A CN104105481A (zh) 2012-02-13 2013-02-12 氢化可的松控制释放制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380008921.6A Division CN104105481A (zh) 2012-02-13 2013-02-12 氢化可的松控制释放制剂

Publications (1)

Publication Number Publication Date
CN110141557A true CN110141557A (zh) 2019-08-20

Family

ID=45930017

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910452557.1A Pending CN110141557A (zh) 2012-02-13 2013-02-12 氢化可的松控制释放制剂
CN201380008921.6A Pending CN104105481A (zh) 2012-02-13 2013-02-12 氢化可的松控制释放制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380008921.6A Pending CN104105481A (zh) 2012-02-13 2013-02-12 氢化可的松控制释放制剂

Country Status (29)

Country Link
US (2) US9750704B2 (https=)
EP (1) EP2814469B1 (https=)
JP (1) JP6293678B2 (https=)
KR (1) KR102023559B1 (https=)
CN (2) CN110141557A (https=)
AU (1) AU2013220139B2 (https=)
BR (1) BR112014020008B1 (https=)
CA (1) CA2864031C (https=)
CY (1) CY1123202T1 (https=)
DK (1) DK2814469T3 (https=)
ES (1) ES2792069T3 (https=)
GB (2) GB201202433D0 (https=)
HK (1) HK1203824A1 (https=)
HR (1) HRP20200780T1 (https=)
HU (1) HUE048904T2 (https=)
IL (2) IL234061B (https=)
IN (1) IN2014DN06808A (https=)
LT (1) LT2814469T (https=)
ME (1) ME03742B (https=)
MX (1) MX361407B (https=)
NZ (2) NZ627468A (https=)
PL (1) PL2814469T3 (https=)
PT (1) PT2814469T (https=)
RS (1) RS60346B1 (https=)
RU (1) RU2619869C2 (https=)
SI (1) SI2814469T1 (https=)
SM (1) SMT202000286T1 (https=)
WO (1) WO2013121184A1 (https=)
ZA (1) ZA201508728B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
US20160367755A1 (en) * 2015-06-01 2016-12-22 Massachusetts Institute Of Technology System and method for neuroendocrine control
FR3057775B1 (fr) * 2016-10-26 2018-11-02 Crossject Solution pharmaceutique d’hydrocortisone pour dispositif d’injection
KR101982287B1 (ko) * 2019-01-04 2019-05-24 (주)청아굿푸드 천연 추출물 함유 서방성 제제 및 그 제조방법
WO2022152863A1 (en) 2021-01-15 2022-07-21 Galventa Gmbh Pulsatile release caffeine formulation
US11904046B1 (en) 2022-11-14 2024-02-20 Eton Pharmaceuticals, Inc. Hydrocortisone oral liquid formulations
WO2025240605A1 (en) 2024-05-15 2025-11-20 Neurocrine Biosciences, Inc. Combination treatment

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065692A1 (en) * 2004-01-03 2005-07-21 University Of Sheffield Treatment
CN1942176A (zh) * 2004-04-22 2007-04-04 杜奥科特公司 用于糖皮质激素替代疗法的药物组合物
WO2010115615A1 (en) * 2009-04-07 2010-10-14 Duocort Pharma Ab Improved glucocorticoid therapy
US20110159095A1 (en) * 2008-09-19 2011-06-30 Hiep Huatan Treatment of adrenal insufficiency
US20110189293A1 (en) * 2007-12-17 2011-08-04 CombinatoRx, Incoporated Therapeutic regimens for the treatment of immunoinflammatory disorders
WO2012017385A2 (en) * 2010-08-06 2012-02-09 Sofar Spa Beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and process for obtaining them

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6013711A (ja) * 1983-06-21 1985-01-24 ザ、プロクタ−、エンド、ギヤンブル、カンパニ− コルチコステロイドを含有する浸透局所製薬組成物
US4552872A (en) 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
GB2292079B (en) * 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
KR19990077278A (ko) 1996-01-16 1999-10-25 마이클 오코넬 약물의 하부 위장관으로의 국소적 전달
DE19718012C1 (de) 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
EP1315481B1 (de) 2000-08-29 2006-12-06 Mepha AG Arzneimittel zur behandlung von darmerkrankungen
NZ527832A (en) * 2001-03-13 2006-03-31 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms
DE20220917U1 (de) 2001-08-06 2004-08-19 Euro-Celtique S.A. Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
PT1453487E (pt) 2001-11-23 2008-05-13 Procter & Gamble Forma de dosagem farmacêutica com revestimentos múltiplos
DE602004028497D1 (de) 2003-09-15 2010-09-16 Nycomed Gmbh Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
UA96457C2 (ru) * 2006-08-03 2011-11-10 Нитек Фарма Аг Лечение ревматоидного артрита глюкокортикоидами с отсроченным высвобождением
CN101795675A (zh) 2006-11-17 2010-08-04 达沃尔泰拉公司 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送
US20100209520A1 (en) 2007-03-26 2010-08-19 Hiroyuki Kubo Oral pharmaceutical preparation for colon-specific delivery
NZ582836A (en) 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
WO2010113177A2 (en) 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Oral insulin delivery systems for controlling diabetes
US9284416B2 (en) * 2009-11-16 2016-03-15 Evonik Roehm Gmbh Process for converting a solid (meth)acrylate copolymer into a dispersed form by means of a dispersing agent
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065692A1 (en) * 2004-01-03 2005-07-21 University Of Sheffield Treatment
CN1942176A (zh) * 2004-04-22 2007-04-04 杜奥科特公司 用于糖皮质激素替代疗法的药物组合物
US20110189293A1 (en) * 2007-12-17 2011-08-04 CombinatoRx, Incoporated Therapeutic regimens for the treatment of immunoinflammatory disorders
US20110159095A1 (en) * 2008-09-19 2011-06-30 Hiep Huatan Treatment of adrenal insufficiency
WO2010115615A1 (en) * 2009-04-07 2010-10-14 Duocort Pharma Ab Improved glucocorticoid therapy
WO2012017385A2 (en) * 2010-08-06 2012-02-09 Sofar Spa Beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and process for obtaining them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEBONO, M，等: "Novel strategies for hydrocortisone replacement", 《BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM》 *
奚念朱: "《药剂学》", 30 April 1996, 北京：人民卫生出版社 *

Also Published As

Publication number Publication date
BR112014020008A8 (pt) 2018-01-23
RS60346B1 (sr) 2020-07-31
WO2013121184A1 (en) 2013-08-22
CN104105481A (zh) 2014-10-15
EP2814469A1 (en) 2014-12-24
CY1123202T1 (el) 2021-10-29
US10166194B2 (en) 2019-01-01
ME03742B (me) 2021-04-20
JP6293678B2 (ja) 2018-03-14
BR112014020008B1 (pt) 2022-05-24
RU2619869C2 (ru) 2017-05-18
HRP20200780T1 (hr) 2020-10-02
RU2014130866A (ru) 2016-04-10
EP2814469B1 (en) 2020-04-08
US9750704B2 (en) 2017-09-05
MX361407B (es) 2018-12-04
KR102023559B1 (ko) 2019-09-23
MX2014009716A (es) 2015-01-14
ZA201508728B (en) 2017-09-27
IL234061B (en) 2018-03-29
PT2814469T (pt) 2020-05-22
GB201302406D0 (en) 2013-03-27
CA2864031C (en) 2019-11-12
NZ715616A (en) 2017-03-31
DK2814469T3 (da) 2020-05-04
KR20140121478A (ko) 2014-10-15
IL234061A0 (en) 2014-09-30
ES2792069T3 (es) 2020-11-06
JP2015506972A (ja) 2015-03-05
US20140370113A1 (en) 2014-12-18
PL2814469T3 (pl) 2020-07-13
HUE048904T2 (hu) 2020-08-28
SI2814469T1 (sl) 2020-07-31
IN2014DN06808A (https=) 2015-05-22
GB2502402B (en) 2014-11-12
GB2502402A (en) 2013-11-27
CA2864031A1 (en) 2013-08-22
HK1203824A1 (en) 2015-11-06
IL245546A0 (en) 2016-06-30
AU2013220139B2 (en) 2017-08-31
AU2013220139A1 (en) 2014-08-07
LT2814469T (lt) 2020-05-25
SMT202000286T1 (it) 2020-07-08
US20170296475A1 (en) 2017-10-19
NZ627468A (en) 2016-02-26
GB201202433D0 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
US10166194B2 (en) Hydrocortisone controlled release formulation
EP1432411B1 (en) Timed, sustained release multi-particulate dosage forms of propranolol
CN1404389B (zh) 时控脉冲给药系统
EP1940361B1 (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20040047906A1 (en) Timed, sustained release systems for propranolol
HUP0302086A2 (hu) Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására
JP7787190B2 (ja) センタナファジン製剤ならびにその製造および使用方法
KR20010111563A (ko) 다입자 변형 방출 조성물
JP2005508922A6 (ja) プロプラノロールの時限徐放性多粒子剤型
EP3010491A1 (en) Delayed release cysteamine bead formulation
JP2005521682A (ja) 結腸放出組成物
ZA200505180B (en) Process for manufacturing sustained release microbeads containing venlafaxine HCI
CN101478958A (zh) 包含哌啶烷醇和减充血剂的组合的药物组合物
JP2007531727A (ja) Ｇａｂａｂ受容体アゴニストを含有する即時放出特性および／または制御放出特性を有する薬学的剤形
CN114425046A (zh) 一种盐酸地尔硫卓缓释胶囊
GB2510754A (en) Delayed release hydrocortisone composition
HK40098701A (zh) 森塔纳法啶药物制剂及其制备和使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: Britain

Address after: Cardiff, England

Applicant after: Newrock Lane UK Ltd.

Address before: Cardiff, England

Applicant before: Diurnal Ltd.

Country or region before: Britain

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190820